554 related articles for article (PubMed ID: 26979641)
1. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
2. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
3. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
4. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
5. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
[TBL] [Abstract][Full Text] [Related]
6. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
[TBL] [Abstract][Full Text] [Related]
7. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
[TBL] [Abstract][Full Text] [Related]
8. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
Zang RY; Harter P; Chi DS; Sehouli J; Jiang R; Tropé CG; Ayhan A; Cormio G; Xing Y; Wollschlaeger KM; Braicu EI; Rabbitt CA; Oksefjell H; Tian WJ; Fotopoulou C; Pfisterer J; du Bois A; Berek JS
Br J Cancer; 2011 Sep; 105(7):890-6. PubMed ID: 21878937
[TBL] [Abstract][Full Text] [Related]
9. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
Hall M; Savvatis K; Nixon K; Kyrgiou M; Hariharan K; Padwick M; Owens O; Cunnea P; Campbell J; Farthing A; Stumpfle R; Vazquez I; Watson N; Krell J; Gabra H; Rustin G; Fotopoulou C
Ann Surg Oncol; 2019 Sep; 26(9):2943-2951. PubMed ID: 31243666
[TBL] [Abstract][Full Text] [Related]
10. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.
Raspagliesi F; Bogani G; Ditto A; Martinelli F; Chiappa V; Borghi C; Scaffa C; Morano F; Maltese G; Lorusso D
Ann Surg Oncol; 2017 Oct; 24(11):3396-3405. PubMed ID: 28795373
[TBL] [Abstract][Full Text] [Related]
11. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
[TBL] [Abstract][Full Text] [Related]
13. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
[TBL] [Abstract][Full Text] [Related]
15. Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database.
McNally L; Teng NN; Kapp DS; Karam A
Int J Gynecol Cancer; 2015 May; 25(4):607-15. PubMed ID: 25756404
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
Huang LP; Yu YH; Sheng C; Wang SH
Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
[TBL] [Abstract][Full Text] [Related]
18. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
